High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

Diabetologia

Volumn 54, Issue 11, 2011, Pages 2965-2967

  Roscioni, S S ^a   Miao, Y ^a   De Zeeuw, D ^a   Lambers Heerspink, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Diabetic nephropathy; End stage renal disease; Hyperkalaemia, Losartan; Serum potassium

Indexed keywords

LOSARTAN; POTASSIUM; RAMIPRIL; TELMISARTAN;

ALBUMINURIA; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 80054688186     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2306-2     Document Type: Article

References (5)

1. Gonçalves AR, El Nahas AM (2011) High serum potassium levels after using losartan can reflect more severe renal disease. Diabetologia doi: 10.1007/s00125-011-2220-7
2. Y Miao D Dobre HJ Heerspink, et al. 2011 Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial Diabetologia 54 44 50 20882268 10.1007/s00125-010-1922-6 1:CAS:528:DC%2BC3cXhsFWqtLvF Erratum in 54:2209
3. JF Mann RE Schmieder M McQueen, et al. 2008 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547 553 18707986 10.1016/S0140-6736(08)61236-2 1:CAS:528:DC%2BD1cXpvFKgsLs%3D
4. BM Brenner ME Cooper D de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 11565518 10.1056/NEJMoa011161 1:CAS:528: DC%2BD3MXntlelsLk%3D
5. B Dahlof RB Devereux SE Kjeldsen, et al. 2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995 1003 11937178 10.1016/S0140-6736(02)08089-3 1:CAS:528:DC%2BD38XisV2htrw%3D (Pubitemid 34286536)